Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer.

about

Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer.

Item

http://www.wikidata.org/entity/Q55634822

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Meta-analysis comparing upfron ...... resectable pancreatic cancer.

@en

Meta-analysis comparing upfron ...... resectable pancreatic cancer.

@nl

type

Item

label

Meta-analysis comparing upfron ...... resectable pancreatic cancer.

@en

Meta-analysis comparing upfron ...... resectable pancreatic cancer.

@nl

prefLabel

Meta-analysis comparing upfron ...... resectable pancreatic cancer.

@en

Meta-analysis comparing upfron ...... resectable pancreatic cancer.

@nl

P1476

Meta-analysis comparing upfron ...... e resectable pancreatic cancer

@en

P2093

C H J van Eijck

http://www.w3.org/2001/XMLSchema#string

C R N Rasch

http://www.w3.org/2001/XMLSchema#string

Dutch Pancreatic Cancer Group

http://www.w3.org/2001/XMLSchema#string

G van Tienhoven

http://www.w3.org/2001/XMLSchema#string

J A Vogel

http://www.w3.org/2001/XMLSchema#string

J W Wilmink

http://www.w3.org/2001/XMLSchema#string

M G Besselink

http://www.w3.org/2001/XMLSchema#string

O R C Busch

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial-NoDerivatives

P2860

Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration

Neoadjuvant radiation is associated with improved survival in patients with resectable pancreatic cancer: an analysis of data from the surveillance, epidemiology, and end results (SEER) registry.

A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: gemcitabine alone versus gemcitabine combined with cisplatin.

Neoadjuvant chemoradiation in patients with potentially resectable pancreatic cancer.

A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer.

Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer.

Sequential neoadjuvant chemoradiotherapy (CRT) followed by curative surgery vs. primary surgery alone for resectable, non-metastasized pancreatic adenocarcinoma: NEOPA- a randomized multicenter phase III study (NCT01900327, DRKS00003893, ISRCTN82191

Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study).

P304

946-958

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

meta-analysis

P356

10.1002/BJS.10870

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

105

http://www.w3.org/2001/XMLSchema#string

P50

Joost Daams

E Versteijne

B Groot Koerkamp

P5008

ScienceSource

P577

2018-04-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29708592

http://www.w3.org/2001/XMLSchema#string

P921

pancreatic cancer

pancreatic neoplasm

P932

6033157

http://www.w3.org/2001/XMLSchema#string